Trial Profile
Phase II and Pharmacokinetic Study of Avastin and Doxil in the Treatment of Platinum-Resistant or Refractory Ovarian Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Oct 2019
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Doxorubicin liposomal (Primary)
- Indications Ovarian cancer
- Focus Pharmacokinetics
- 18 Jun 2012 Actual end date Jun 2012 added as reported by ClinicalTrials.gov.
- 18 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.